. 2021 Feb 24;10(2):e22511. doi: 10.2196/22511

Table 1.

Trial visits summary.

Time point		Enrollment	Allocation	Postallocation			Close-out
		−t₁	0	t0	15 min	12 h	Day 1	Days 2,3,4,7	Day 15	Days 15-90	Day 90
Enrollment
	Eligibility screen	✓^a	—^b	—	—	—	—	—	—	—	—
	Informed consent	✓	—	—	—	—	—	—	—	—	—
	Allocation	—	✓	—	—	—	—	—	—	—	—
Interventions
	Valproate dosage	—	—	✓	✓	✓	—	—	—	—	—
Assessments
	Clinical assessment	✓	✓	✓	✓	✓	✓	✓	✓	—	—
	CAM-ICU^c, GCS^d, and RASS^e	—	—	✓	✓	✓	✓	✓	✓	—	—
	Etiological investigation	—	—	✓	✓	✓	✓	✓	✓	—	—
	Standard EEG^f	—	—	—	—	—	✓	✓	✓	—	—
	SOFA^g	—	—	✓	—	✓	✓	✓	✓	—	—
	SAPS-II^h	—	—	—	—	—	✓	—	—	—	—
	FABⁱ, MMSE^j, GOSE^k, and SF-36^l	—	—	—	—	—	—	—	—	—	✓
	Valproate adverse effects reporting	—	—	✓	—	✓	✓	✓	✓	—	—
	Primary outcome	—	—	—	—	—	—	—	✓	—	—
	Secondary outcome	—	—	✓	—	✓	—	—	—	—	—
	End of trial criteria	—	—	—	—	—	—	—	—	—	—

^a✓: visit is scheduled.

^bAbsence of visits.

^cCAM-ICU: Confusion Assessment Method for the Intensive Care Unit.

^dGCS: Glasgow Coma Scale.

^eRASS: Richmond Agitation-Sedation Scale.

^fEEG: electroencephalogram.

^gSOFA: sepsis-related organ failure assessment.

^hSAPS-II: Simplified Acute Physiology Score.

ⁱFAB: Frontal Assessment Battery.

^jMMSE: Mini-Mental State Examination.

^kGOSE: Glasgow Outcome Scale-Extended.

^lSF-36: Short Form-36.